Ken Griffin
VIR icon

Ken Griffin’s Vir Biotechnology VIR Stock Holding History

Ken Griffin’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,800
Closed -$246K – 14318
2025
Q4 		$246K Buy
40,800
+22,300
+121% +$133K ﹤0.01% 10589
2025
Q3 		$106K Sell
18,500
-2,100
-10% -$10.7K ﹤0.01% 11820
2025
Q2 		$104K Sell
20,600
-8,300
-29% -$44.5K ﹤0.01% 11314
2025
Q1 		$187K Buy
28,900
+7,700
+36% +$68.5K ﹤0.01% 10544
2024
Q4 		$156K Sell
21,200
-10,200
-32% -$80.5K ﹤0.01% 10823
2024
Q3 		$235K Buy
31,400
+10,800
+52% +$93.8K ﹤0.01% 9824
2024
Q2 		$183K Sell
20,600
-7,500
-27% -$71.9K ﹤0.01% 10064
2024
Q1 		$285K Buy
28,100
+6,700
+31% +$68.2K ﹤0.01% 9564
2023
Q4 		$215K Sell
21,400
-17,600
-45% -$161K ﹤0.01% 9811
2023
Q3 		$365K Sell
39,000
-5,500
-12% -$78.4K ﹤0.01% 8742
2023
Q2 		$1.09M Buy
44,500
+12,000
+37% +$301K ﹤0.01% 6283
2023
Q1 		$756K Sell
32,500
-16,700
-34% -$427K ﹤0.01% 7395
2022
Q4 		$1.25M Sell
49,200
-3,400
-6% -$83.3K ﹤0.01% 6390
2022
Q3 		$1.01M Sell
52,600
-5,400
-9% -$137K ﹤0.01% 6965
2022
Q2 		$1.48M Sell
58,000
-96,600
-62% -$2.26M ﹤0.01% 6159
2022
Q1 		$3.98M Sell
154,600
-44,200
-22% -$1.31M ﹤0.01% 4624
2021
Q4 		$8.32M Buy
198,800
+114,300
+135% +$4.48M ﹤0.01% 3366
2021
Q3 		$3.68M Buy
84,500
+13,500
+19% +$584K ﹤0.01% 4921
2021
Q2 		$3.36M Sell
71,000
-3,500
-5% -$159K ﹤0.01% 5331
2021
Q1 		$3.82M Buy
74,500
+14,000
+23% +$755K ﹤0.01% 4878
2020
Q4 		$1.62M Buy
60,500
+37,800
+167% +$1.23M ﹤0.01% 5825
2020
Q3 		$779K Sell
22,700
-7,900
-26% -$340K ﹤0.01% 6488
2020
Q2 		$1.25M Buy
+30,600
New +$1.03M ﹤0.01% 5411

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ken Griffin's VIR Position: Q1 2026 in Review

Ken Griffin increased its Vir Biotechnology (VIR) stake by 329% in Q1 2026, buying an estimated $12.8M and bringing the position to 2,098,476 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

Ken Griffin first reported a position in VIR in Q4 2019 and has held it in 23 quarters since. The position peaked at $34.5M in Q1 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Ken Griffin held 2,098,476 shares of Vir Biotechnology worth $18.8M as of Q1 2026.
  • Ken Griffin bought 1,609,250 Vir Biotechnology shares in Q1 2026, an estimated $12.8M.
  • Vir Biotechnology made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2402 holding.
  • Ken Griffin first reported a position in Vir Biotechnology in Q4 2019 and has held it in 23 quarters since.
  • Ken Griffin's Vir Biotechnology position peaked at $34.5M in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.